A US judge has opened the door to generic versions of heart disease drug Vascepa (icosapent ethyl), after invalidating Amarin’s key patents covering the drug.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
22 June 2021 Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
22 June 2021 Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
22 June 2021 Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.
